Skip to main content
← All trials
Solid TumorsGeneticsCancerDrugPhase 3

What this study is

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

What's being tested

  • INCB161734

    Intervention · DRUG

  • Placebo

    Intervention · DRUG

  • Investigator's choice of chemotherapy

    Intervention · DRUG

    The investigator will select the chemotherapy in accordance with the protocol-defined requirements. The possible choices as defined by the protocol:

Both INCB161734 and Placebo

Oral; tablet

Study details

Official title
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
Sponsor
Incyte Corporation
Conditions
Solid Tumors
Enrolling
588 people
Starts
2026-04-09
Est. completion
2029-03-19
Design
Double-blind, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗